Welcome to our dedicated page for Mirati Therapeutics news (Ticker: MRTX), a resource for investors and traders seeking the latest updates and insights on Mirati Therapeutics stock.
Mirati Therapeutics, Inc. (NASDAQ: MRTX) is a commercial stage biotechnology company focused on pioneering breakthrough therapies to transform the lives of patients with cancer. Specializing in molecularly targeted and immuno-oncology combination therapies, Mirati is at the forefront of cancer treatment innovation. The core of Mirati's mission is to develop drug candidates that target genetic and epigenetic drivers of cancer. The company leverages a strategic approach that includes selecting patients whose tumors depend on specific genetic alterations and employing a highly accomplished leadership team in oncology precision medicine.
Mirati Therapeutics is advancing three primary drug candidates through clinical development for multiple oncology indications. Their flagship product, KRAZATI® (adagrasib), has shown promising results in treating non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation. Adagrasib offers potential best-in-class efficacy, particularly for patients with central nervous system metastases. Notably, the drug has been granted conditional marketing authorization by the UK's MHRA and the European Commission, highlighting its impactful role in current cancer treatment paradigms.
Mirati's innovative pipeline also includes MRTX1719, a PRMT5 inhibitor, and MRTX1133, a selective KRASG12D inhibitor, both of which are designed to address high unmet medical needs. The company recently completed an upsized public offering, extending its cash runway to support upcoming milestones.
In recent developments, Mirati announced that Laurie Stelzer, Chief Financial Officer, will depart the company in September 2023, with Aaron Ondrey stepping in as interim CFO. This transition comes at a pivotal time as Mirati continues to advance its clinical programs and prepare for potential new product launches.
With a relentless focus on patient outcomes, Mirati's vision is to unlock the science behind a life beyond cancer. The company continues to collaborate with global healthcare regulators and partners to ensure broad access to its groundbreaking therapies.
Mirati Therapeutics (NASDAQ: MRTX) will present initial preclinical data on its PRMT5 inhibitor during a late-breaking symposium at the AACR Virtual Annual Meeting from April 10-15, 2021. The drug targets the methylthioadenosine phosphorylase (MTAP)-deleted patient population, commonly seen in cancers like pancreatic and lung. James Christensen, Ph.D., highlighted the company's commitment to creating targeted therapies. The presentation, titled 'Fragment based discovery of MRTX9768,' will take place on April 10, 2021, from 1:30 p.m. to 3:30 p.m.
Mirati Therapeutics, Inc. (NASDAQ: MRTX) reported its 2020 Q4 and full-year results, showing progress in its oncology pipeline. Key highlights include:
- Cash reserves stand at $1.4 billion.
- License and collaboration revenues of $1.7 million for Q4 and $13.4 million for 2020.
- Research and development expenses rose to $82.7 million for Q4 and $299.3 million for the full year.
- Net loss increased to $101.1 million in Q4, totaling $357.9 million for the year.
Mirati aims to accelerate development with new clinical trials for adagrasib and MRTX1133.
Mirati Therapeutics (NASDAQ: MRTX), a late-stage oncology firm, will present at two key healthcare conferences in late February and early March 2021. The first presentation is on February 26 at the 10th Annual SVB Leerink Global Healthcare Conference, featuring Dan Faga in a fireside chat. The second is on March 3 at the 41st Annual Cowen Healthcare Conference, with Charles M. Baum leading the discussion. Both presentations will be available via webcast on the company's website for 90 days after the events.
Mirati Therapeutics (NASDAQ: MRTX) has partnered with MD Anderson Cancer Center to enhance the development of its KRAS inhibitors, notably adagrasib (MRTX849) and MRTX1133, targeting prevalent KRAS mutations in various cancers. This collaboration will utilize MD Anderson's clinical trial expertise over five years, focusing on solid tumors like lung and pancreatic cancers. Mirati will fund and support the research, aiming to accelerate new treatment options for patients with unmet medical needs.
Mirati Therapeutics (NASDAQ: MRTX) announced participation in a fireside chat at Guggenheim Healthcare Talks 2021 Oncology Days on February 11, 2021, at 9:00 a.m. ET. Dan Faga, Executive Vice President and COO, will represent the company. The event will be webcasted and available on their website, with a replay accessible for 90 days. Mirati is focused on advancing treatments targeting genetic drivers of cancer, particularly with investigational drugs like adagrasib for non-small cell lung cancer and sitravatinib, enhancing immune responses in patients.
Mirati Therapeutics (NASDAQ: MRTX), a targeted oncology company, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 12:40 p.m. PST. CEO Charles M. Baum will lead the presentation, which will be accessible via webcast on their website. The company is focused on innovative cancer treatments, with programs like adagrasib for NSCLC in clinical trials and the development of MRTX1133 and sitravatinib for various tumor types.
Mirati Therapeutics, Inc. (NASDAQ: MRTX) announced participation in the 2020 Evercore ISI HealthCONx Conference on December 1 at 8:20 a.m. PT. Dan Faga, Executive Vice President and COO, will represent the company. The event will be available via a webcast on the company's website, with a replay accessible for 90 days. Mirati focuses on developing novel therapeutics targeting cancer's genetic and immunologic drivers. Their pipeline includes adagrasib, a KRAS G12C inhibitor, and sitravatinib, an RTK inhibitor, with ongoing studies for treating non-small cell lung cancer.
Mirati Therapeutics (NASDAQ: MRTX) will participate in the 29th Annual Credit Suisse Virtual Healthcare Conference on November 12, 2020, at 9:30 a.m. PT. Dan Faga, Executive VP and COO, will represent the company. A webcast of the event will be available on the Mirati website, and a replay will be accessible for 90 days post-event. Mirati is focused on developing targeted oncology treatments, with promising pipelines like adagrasib and sitravatinib aimed at treating various cancers, including non-small cell lung cancer.
Mirati Therapeutics (MRTX) reported Q3 financial results and business highlights on November 4, 2020. The company ended Q3 with $579.1 million in cash following a public offering that raised $879.7 million. License and collaboration revenues increased to $11.4 million, up from $1 million in Q3 2019. However, R&D expenses surged to $79.9 million, causing a net loss of $87.3 million, or $1.96 per share, compared to a loss of $54.3 million in Q3 2019. Progress included the completion of patient enrollment in a Phase 2 trial for adagrasib and presentation of promising preclinical data for MRTX1133.
Mirati Therapeutics (Nasdaq: MRTX) has successfully closed an underwritten public offering of 4,985,706 shares of common stock at $202.00 per share. The offering included 4,585,706 shares from Mirati and 400,000 from a selling stockholder, with gross proceeds approximating $926.3 million. This includes the complete exercise of underwriters' options for additional shares. The funds raised will likely support the company's ongoing development of its cancer therapeutics pipeline, including adagrasib and sitravatinib.
FAQ
What is the market cap of Mirati Therapeutics (MRTX)?
What does Mirati Therapeutics specialize in?
What are the main drug candidates of Mirati Therapeutics?
What recent approvals has KRAZATI® received?
Who is the interim Chief Financial Officer of Mirati Therapeutics?
What is the focus of Mirati's drug development strategy?
Where can I find more information about Mirati's clinical trials?
How does Mirati's adagrasib (KRAZATI) differ from other cancer treatments?
What recent corporate updates has Mirati announced?
What is the mission of Mirati Therapeutics?
How can investors contact Mirati Therapeutics?
